BAJAJ BROKING
Apollo Hospitals posted a 53.5% YoY rise in net profit to Rs.390 crore in Q4 FY25, exceeding Street estimates. Revenue grew 13% to Rs.5,592 crore. The board declared a final dividend of Rs.10 per share, with a record date set for August 19, 2025.
Apollo Hospitals Enterprise delivered a strong Q4 FY25, reporting a net profit of Rs.390 crore, up 53.5% from Rs.254 crore in the same quarter last year. Revenue from operations increased 13% YoY to Rs.5,592 crore, compared to Rs.4,944 crore in Q4 FY24.
Sequentially, net profit rose 5% from Rs.372 crore in Q3 FY25, while revenue showed a modest 1.2% growth over Rs.5,527 crore in the previous quarter. Total expenses increased to Rs.5,148 crore in Q4 from Rs.4,612 crore in Q4 FY24, reflecting higher input, staffing, and finance costs.
The board recommended a final dividend of Rs.10 per equity share for FY25, with the record date fixed as August 19, 2025.
Q4 FY25 net profit grew 53.5% YoY to Rs.390 crore.
Revenue from operations rose 13% YoY to Rs.5,592 crore.
Sequential net profit rose 5% from Rs.372 crore in Q3 FY25.
Expenses climbed to Rs.5,148 crore from Rs.4,612 crore in Q4 FY24.
Final dividend of Rs.10 per share announced; record date set as August 19, 2025.
Net profit beat Street expectations of Rs.374 crore.
Apollo Hospitals’ strong performance this quarter reflects its continued leadership in healthcare services and growth in digital healthcare platforms. Focused execution, cost optimisation, and scale benefits helped deliver stronger-than-expected earnings.
The company is expected to build further on its integrated care ecosystem — spanning hospitals, diagnostics, pharmacies, and digital engagement through Apollo 24/7 — to drive future profitability. Ongoing investments in specialty care, regional expansion, and technology adoption remain key pillars of its FY26 strategy.
India’s healthcare sector is witnessing rising demand, led by urbanisation, insurance penetration, and increased public-private collaboration. Large hospital chains like Apollo are likely to benefit from operating leverage, digital health integration, and increasing outpatient and elective procedure volumes.
With tailwinds from policy support and rising medical tourism, Apollo is well-placed to sustain growth in FY26, supported by scale, brand trust, and clinical excellence.
Metric | Q4 FY25 | Q4 FY24 | Q3 FY25 |
Net profit (Rs. crore) | 390.0 | 254.0 | 372.0 |
Revenue from operations | 5,592.0 | 4,944.0 | 5,527.0 |
Total expenses | 5,148.0 | 4,612.0 | 5,060.0 |
Dividend per share (Rs.) | 10.00* | — | — |
Record date | 19 Aug 2025 | — | — |
*Final dividend for FY25 as per board recommendation.
Source: Apollo Hospitals Enterprise Ltd – Audited Q4 FY25 Financial Results & Stock Exchange Filings
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading